GeneCentric’s mission is to address the urgent unmet need in precision oncology for better biomarkers and to bring these biomarkers to liquid biopsies. Through AI and the inherent multimodal output of our GenomicsNext™ platform, we are accelerating liquid biopsy advancements. Building on over a decade of expertise with gene expression, we developed ExpressCT™, a breakthrough technology that measures gene expression using information embedded in circulating tumor DNA (ctDNA), to provide a more complete liquid biopsy solution for precision medicine. ExpressCT™ meets the genomic testing field today through its ability to analyze retrospective genomic ctDNA sequence data and expands the reach and utility of ctDNA sequencing beyond alterations alone. We are actively leveraging our platform through strategic collaborations with diagnostics, pharmaceutical and biotechnology companies.